

For Immediate Release

MedX Health Corp Announces Date For Annual Meeting

Mississauga, ON – January 21, 2010 – MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced it will be holding its annual meeting for the year ended December 31, 2008 on February 26th, 2010, at 10 a.m., at its headquarters at 220 Superior Blvd., Mississauga, ON.

MedX is in default of TSX Venture Exchange (the “Exchange”) requirements for failing to hold its annual general meeting within the timeframes required by applicable corporate law and Exchange policy and this disclosure is being provided at the request of the Exchange. Materials for the meeting will be mailed to registered holders and posted on SEDAR shortly.

MedX apologizes for the late holding of the 2008 annual meeting which was caused primarily by personnel changes and in particular the previously announced resignation of the CFO. MedX has engaged the services of an experienced financial executive, Chris Jamieson, to assist us in performing the CFO function including ensuring ongoing compliance with applicable corporate law and Exchange policy.

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world’s only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for, the bringing of non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX’s strategy is to build upon its success in bringing relief of conditions in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its “*Photobandage*™”, a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit www.medXhealth.com

Contacts:

Investors:

Steve Guillen
President and Chief Executive Officer
MedX Health Corp.
Phone: (905) 826-0766
info@medxhealth.com

Media:

Terri Clevenger
Continuum Health Communications
Phone (203) 227-0209
Email: tclevenger@continuumhealthcom.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.